Krensavage Asset Management Buys $5.4M in Ultragenyx as Shares Drop 30% Year-to-Date
On May 14, Krensavage Asset Management disclosed a purchase of 241,245 shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) for an estimated $5.4 million during Q1 2026. Despite the fund's increased stake and a rise in position value to $8.19 million by quarter-end, RARE stock has fallen over 30% year-to-date.
Tickers: $RARE
Topics: Krensavage Asset Management SEC filing stock purchase Ultragenyx Pharmaceutical